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PENILAIAN HUBUNGKAIT STATIN DENGAN KAWALAN HBA1C 
DAN FUNGSI KOGNITIF, KESEDARAN PROFESIONAL KESIHATAN 
TENTANG PENGGUNAAN STATIN DALAM KALANGAN PESAKIT 
DIABETES DI PULAU PINANG 
 
 
ABSTRAK 
 
          Statin merupakan kelas ubat yang paling kerap dipreskripsi dan manfaatnya dalam 
terapi dislipidemia dan mengurangkan risiko penyakit jantung koronari telah dilaporkan 
dengan jelas.  Namun begitu, kesan statin terhadap hasilan bukan kardiovaskular masih 
tidak jelas.  Kajian ini bertujuan untuk menilai epidemiologi penggunaan statin dan 
kesannya terhadap kawalan hemoglobin glikasi (HbA1c) dan ketakmampuan kognitif 
dalam kalangan pesakit diabetes melitus jenis 2.  Kajian ini juga bertujuan untuk 
mengukur kelaziman dan impak glisemia terkawal (CG) terhadap morbiditi dan anggaran 
kelangsungan hidup sepuluh tahun (ES-10Y). Sebagai tambahan, kajian ini juga bertujuan 
menilai pengetahuan, sikap dan amalan (KAP) ahli farmasi dan pakar perubatan tentang 
penggunaan statin dalam pesakit diabetik. Kira-kira 1400 orang pesakit dinilai dalam satu 
kajian keratan rentas di hospital Pulau Pinang, Malaysia, bagi menilai kelaziman 
preskripsi statin dan CG (HbA1c ≤7%) dinilai.  Dalam kajian kohort prospektif, seramai 
213 pengguna statin dan 187 bukan pengguna statin diikuti selama satu tahun untuk 
mengenal pasti kesan statin terhadap kawalan glisemik.  Indeks Komorbiditi Charlson 
[Charson Comorbidity Index (CCI)] digunakan untuk mengira impak pembauran 
komorbiditi dan meramal ES-10Y dalam kalangan pesakit CG dan glisemia tidak terkawal 
(UCG).  Ujian Kognitif Mini-Addenbrooke [Mini-Addenbrooke's Cognitive Examination 
xxii 
 
(M-ACE)] versi bahasa Melayu disesuai dan disahkan untuk menilai ketakmampuan 
kognitif dalam kalangan pesakit diabetes.  Satu tinjauan KAP dibuat dan disahkan untuk 
meninjau kesedaran ahli penjagaan kesihatan tentang penggunaan statin dalam 
pengurusan dislipidemia diabetik (DDM). Daripada 757 orang pesakit, kira-kira 372 
orang pesakit (49.1%) mempunyai UCG dan lebih daripada 102 daripada mereka (27.4%) 
mempunyai HbA1c melebihi 10%.  Kira-kira 74.5% daripada pesakit diberikan terapi 
statin.  Dalam analisis prospektif, seramai 400 pesakit diagihkan kepada kumpulan 
penerima rawatan, HbA1c 8.66 ± 1.77 dan kumpulan kawalan, HbA1c 7.89 ± 1.92 (P 
<0.001).  Daripada 213 kumpulan yang menjalani terapi, kira-kira 145 orang pesakit 
(68.1%) mempunyai UCG.  Daripada 187 pesakit dalam kumpulan kawalan, seramai 78 
orang pesakit (41.7%) mempunyai UCG.  Risiko relatif (RR) UCG bagi pesakit diabetes 
yang menggunakan statin adalah 1.63 [95% CI: 1.35-1.98].  Statin intensiti dos tinggi 
(HDI) mempunyai risiko UCG yang lebih tinggi, berbanding dengan intensiti dos 
sederhana (MDI) dan statin intensiti dos rendah (LDI) (RR: 1.26%, 95% CI: 1.04-1.54).  
Skor CCI untuk CG dan UCG masing-masing ialah 3.38 ± 2.38 dan 4.42 ± 2.70 (P: 0.001), 
ES-10Y adalah 62% dan 46.2% (P: 0.001).  M-ACE menunjukkan bahawa RR 
ketakmampuan kognitif bersangkutan dengan penggunaan statin dalam pesakit diabetes 
adalah 1.72, (95% CI: 1.2 - 2.48). Dalam kajian KAP, doktor mewakili 78.5% dan ahli 
farmasi mewakili 21.5% responden.  Hampir 21% daripada pasukan penjagaan kesihatan 
mempunyai kelayakan pascasiswazah (PGQ).  Responden mempunyai pengalaman purata 
selama (5.3 ± 5.7) tahun.  Pengetahuan responden mengenai statin adalah 75.2%.  Skor 
amalan responden adalah 55.8%.  Kira-kira 61% daripada mereka mempunyai sikap 
positif terhadap terapi statin dalam DDM manakala 19.5% daripada responden 
mempunyai sikap negatif dan 19.5% responden mempunyai sikap neutral.  Skor purata 
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KAP bagi peserta yang memiliki PGQ jauh lebih tinggi daripada ahli penjagaan kesihatan 
tanpa PGQ; [(72.9 ± 18 berbanding 64.2 ± 15.6), (Z: -4.26, P: 0.001)]. Kepatuhan yang 
lebih terhadap panduan yang mencadangkan statin bagi pesakit diabetes jenis 2 sebagai 
kunci kepada terapi profilaksis adalah diperlukan. Kepatuhan ini memainkan peranan 
yang penting bagi memastikan kejayaan dalam memutuskan preskripsi dan penggunaan 
statin. Tambahan pula, usaha bagi memastikan pengoptimuman penggunaan dan 
preskripsi statin mampu membantu mencapai hasilan klinikal terapi statin yang lebih baik 
dalam DDM dan mengurangkan kesan sampingan berkaitan penggunaan statin. 
Walaubagaimanapun, masih terdapat keperluan untuk pembangunan professional 
berterusan (CPD) dan kelangsungan praktis lanjutan dalam pegoptimuman terapi statin. 
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EVALUATION OF STATIN ASSOCIATION WITH HBA1C CONTROL, COGNITIVE 
FUNCTION AND HEALTHCARE PROFESSIONAL'S AWARENESS OF STATIN 
USAGE AMONG DIABETIC PATIENTS IN PENANG 
 
 
ABSTRACT 
  
Statins are the most broadly prescribed class of medications, and their benefits in 
dyslipidemia therapy and diminishing the hazard for coronary heart disease (CHD) are well 
reported, but statins effects on non-cardiovascular outcomes are still unclear. This study aimed 
to assess the epidemiology of statins use and its effect on glycated hemoglobin (HbA1c) 
control and cognitive impairment among type 2 diabetic patients. Moreover, this study also 
aimed to measure the prevalence and impact of controlled glycemia (CG) on morbidity and 
estimated 10-year survival (ES-10Y). Furthermore, it meant to assess the knowledge, attitude, 
and practice (KAP) of pharmacists and physicians about statins use among the diabetic 
patients. About 1400 patients were scanned in a cross-sectional study at Hospital Pulau Pinang, 
Malaysia, the prevalence of statins prescription and CG (HbA1c ≤7%) was assessed. In a 
prospective cohort study, 213 statin users and 187 statin non-users were followed-up for one 
year to identify statin effect on glycemic control. Charlson Comorbidity Index (CCI) was used 
to calculate the confounding impact of comorbidities and to predict ES-10Y among CG and 
uncontrolled glycemia (UCG). Malay version of Mini-Addenbrooke's Cognitive Examination 
(M-ACE) was adapted and validated to assess the cognitive impairment among 280 diabetic 
patients. A KAP survey was constructed and validated to investigate the awareness of 200 
healthcare providers about statins usage in diabetic dyslipidemia management (DDM). Of the 
757 patients had an HbA1c test, about 372 (49.1%) cases had UCG, and more than 102 (27.4%) 
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of them had HbA1c >10%. About 74.5% of cases were prescribed with statin therapy. In the 
prospective analysis, 400 subjects, distributed among treatment cohort with HbA1c (8.66 ± 
1.77), and control group with HbA1c (7.89 ± 1.92) (P <0.001).  From 213 therapy group, about 
145 (68.1%) patients had UCG. Of 187 patients in the control group, 78 (41.7%) patients had 
UCG. The relative risk (RR) of UCG in diabetic patients using statins was 1.63, (95% CI: 
1.35–1.98). Statin treatment with high-dose intensity (HDI) had a higher risk of UCG, 
compared with medium-dose intensity (MDI) and low-dose intensity (LDI) statins (RR: 1.26, 
95% CI: 1.04–1.54). CCI score was 3.38 ± 2.38 vs. 4.42 ± 2.70 (P-value: 0.001) and, ES-10Y 
was 62% vs 46.2% (P-value: 0.001) in CG vs. UCG respectively. M-ACE indicated that the 
RR of a cognitive impairment associated with statins utilization in diabetic patients is 1.72, 
(95% CI: 1.2 – 2.48). In the KAP study, the participants consist of 157 physicians and the 43 
pharmacists. Nearly 21% of healthcare team had a postgraduate qualification (PGQ). The 
subjects had an average experience of (5.3 ± 5.7) years. Subjects’ knowledge about statins was 
75.2%. The score of respondents’ practice was 55.8%. About 61% of them have a positive 
attitude about statins therapy in DDM. While only 19.5% of subjects have a negative attitude 
and same number of participants, have a neutral attitude. The KAP mean scores of participants 
with PGQ were significantly higher than healthcare without PGQ; [(72.9 ± 18 vs. 64.2 ± 15.6), 
P: 0.001]. The study determined that there was a dose-response association between statin 
therapy strength and glycemia control. The possibility of new-onset cognitive decline and the 
damage of existing cognitive deficits should be considered when prescribing a statin to 
patients. Statin therapy was associated with higher odds of adverse reactions compared with 
statins non-users but with substantial clinical benefit. However, patients with multiple medical 
co-morbidities and polypharmacy are at increased risk of adverse reactions from long-term 
statin utilization. More adherence to clinical recommendations that praise statin therapy for 
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diabetic patients as the key to CHD prevention therapy is required. This adherence may play a 
crucial role in ensuring success in the decision of statins prescribing and use. Moreover, 
exertions to guarantee optimization of the use and prescription of statin may help in 
accomplishing superior medical consequences of statin treatment in DDM and decrease side 
effects associated with statin usage. However, still, there is a necessity for more continuing 
professional development (CPD) and sustainable advanced practice in statin therapy 
optimization. 
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CHAPTER 1 : GENERAL INTRODUCTION 
1.1 Statins 
Statins (3-hydroxy-3-methyl-glutaryl-CoA reductase or HMG-CoA reductase 
inhibitors) are a class of medicines used to inhibit the enzyme HMG-CoA reductase and 
decrease cholesterol levels, which achieves an essential role in the synthesis of cholesterol 
in the liver, which creating about seventy percent of the total cholesterol (TC) in the body. 
Dyslipidemia is a well-reported risk factor for many cardiovascular diseases (Prospective 
Studies Collaboration et al., 2007, pp. 1829-39; Nelson, 2013, pp. 195-211). 
Statins are the most widely provided category of drugs in the United States, and 
their benefits for reduction of low-density lipoprotein cholesterol (LDL-C) and reducing 
the risk for coronary heart disease (CHD) are well documented. Statins have been the 
backbone of pharmacotherapy for the treatment of dyslipidemia since their production 
(Cholesterol Treatment Trialists (CTT) Collaboration et al., 2010, pp. 1670-81). 
According to Taylor et al., (2013), statins therapy associated with a reduction of 
cardiovascular disease (CVD) and mortality rate in persons who are in elevated threat of 
CVD. The proof is substantial that statins are a useful therapy for CVD in the initial phases 
of illness (secondary prophylaxis) and persons at high hazard but lacking CVD (primary 
prophylaxis) (p. CD004816).  
Dyslipidemia management no longer be modified to target specific LDL-C or non-
high-density lipoprotein cholesterol (non–HDL-C) goals. Direct starting of statin 
treatment is not recommended for patients with class II-IV heart failure (HF) or those on 
maintenance hemodialysis as a routine (Stone et al., 2014, pp. S1-S45). 
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Starting statins therapy in secondary and primary protection at moderate- to high-
intensity doses showed benefits in the individual with atherosclerotic cardiovascular 
disease (ASCVD), a person has an LDL-C of 4.9 mmol/L or higher. Moreover, statin has 
benefit in diabetic patients with age 40–75 years and an LDL-C of 1.8 – 4.9 mmol/L and 
without ASCVD. Furthermore statin has benefit in individuals with an LDL-C of 1.8 – 
4.9 mmol/L and an evaluated 10-year ASCVD risk of 7.5% or more without diabetes or 
ASCVD (Cholesterol Treatment Trialists (CTT) Collaborators et al., 2010, pp. 1670-81; 
Taylor et al., 2013, p. CD004816).   
1.1.1 Statins safety 
The use of statins in cardiovascular events in patients with cardiovascular risks is 
efficient and safe (Cholesterol Treatment Trialists (CTT) Collaborators et al., 2008, pp. 
117-25).  In the United States (US), the labels of statin medicines, report information 
concerning glycemic effects, including diabetes mellitus and elevating in hemoglobin 
A1c or fasting blood sugar. These labeling changes had approved by the US Food and 
Drug Administration (FDA) in February 2012; depend mainly on evidence taken from 
two meta-analyses of randomized controlled clinical trials (Food and Drug 
Administration, 2012, para. 1). The earliest meta-analysis of statins matched with placebo, 
directed by Rajpathak et al., 2009, included patients from six trials and documented a little 
rise in risk (RR 1.13, 95% CI 1.03–1.23) for type 2 diabetes (pp. 1924-9). The second 
meta-analysis, showed the following year by Sattar and colleagues, investigated the 
consequence of statins usage on the risk of type 2 diabetes in 91 140 patients from thirteen 
trials (Sattar et al., 2010, pp. 735-42).  
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Sattar et al., (2010), showed that statins were accompanied with a nine percent 
increased risk of diabetes in participants receiving statins during an average follow-up 
period of approximately four years. The number required to treat over four years to result 
in one excess case of diabetes was 255. Moreover, in a meta-analysis of five trials, Preiss 
et al., (2011), also compared the risk of diabetes mellitus associated with higher potency 
and lower potency statins and reported that a twelve percent increased the risk of diabetes 
was related to higher potency statins higher than lower potency statins (pp. 2556-64).  
Earlier 2015, the National Pharmaceutical Control Bureau issued a statement 
requesting all statin manufacturers in Malaysia to include the potential for increases in 
fasting blood glucose (FBG) and HbA1c with statins in the drug information leaflet in 
response to FDA report (p. 496). On the other hand, a limited study has been conducted 
in Malaysia regarding this warning label, but still there is some uncertainty whether such 
risk can also be detected in the Malaysian population or not (Atorvastatin Winthrop 
Tablet, 2015, para. 1). 
Following a review of potential side effects, the UK Medicines and Healthcare 
Products Regulatory Agency (MHRA) (2009) decided that memory loss should be listed 
as a side effect in the product information for all statins (para. 1). Similarly, the US FDA 
(2012) required a declaration to be written in the drug label for all statins that there was a 
possible for cognitive side effects (para.1). This decision based on post-marketing event 
reports from persons of ill-defined memory loss or decline that appeared to be reversible 
after stopping statin therapy, and not because there was high-quality evidence for a causal 
link. Indeed, a later evaluation of FDA surveillance databases found the reporting degrees 
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of cognition-associated adverse events for statins to be similar to those of other drugs used 
in patients with atherosclerotic disease (as cited in Collins et al., 2016, pp. 2532-61). 
1.1.2 Prevalence and burden cost of statins 
Ministry of Health Malaysia, The National Medicines Use Survey (NMUS) states 
that: Lovastatin ranked 11th, simvastatin 18th  and atorvastatin 20th in 2010, those have 
been steadily in the top forty drugs used (rank 15th, 20th, and 26th respectively in 2009) 
(Institute for Public Health, 2008, p. 783; Yusof et al., 2010a, pp. 21-28). While in 
Australia, atorvastatin ranked 1st and simvastatin 2nd in the medicine used, and in Norway, 
simvastatin ranked 1st, and atorvastatin ranked 3rd (Australian Government Department of 
Health and Ageing, 2009, para. 1; NIPH, 2008, para. 1). The total expenses of lipid-
modifying agents have increased from RM210.1 million in 2009 to RM328.9 million in 
2010; an increase of more than 50% and it is 2nd ranked. Among the top 40 drugs, the 
highest spending was reported for amlodipine in 2009 (RM123.0 million) and simvastatin 
in 2010 (RM101.2 million). For these two drugs, more than 50% of the total spending was 
related to the private sector. The atorvastatin and simvastatin were for both years in the 
top 10 list of cost (Yusof et al., 2010b, pp. 29-35). 
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1.2 Diabetes Mellitus 
Type 2 diabetes mellitus (Non-Insulin-dependent diabetes mellitus (NIDDM) or 
adult-onset diabetes) is a metabolic syndrome that is characterized by hyperglycemia in 
the context of insulin resistance and a relative shortage of insulin (Kumar, Fausto, Abbas, 
Cotran, & Robbins, 2005, pp. 1194-95). Type 2 diabetes is in contrast to diabetes type 1, 
in which there is a damage of islet cells in the pancreas leading to an absolute shortage of 
insulin (Masharani & German, 2011, para. 1). The classic symptoms are constant hunger 
excess urination and frequent thirst. About 90% of diabetic patients have type 2 diabetes. 
However, the other 10%  represents type 1 diabetes and gestational diabetes.  
1.2.1 Prevalence of Diabetes Mellitus 
In 2015, around 415 million persons in the worldwide, or about nine percent of 
individuals in the age of work, are evaluated to have diabetes. Developing countries 
include 75% of diabetic patients. If these trends continue, by 2040 some 642 million 
people, or one adult in ten, will have diabetes mellitus. Approximately three new cases 
estimated to have diabetes every ten seconds or almost ten million per year (Kamenov, 
2015, pp. 141-58; International Diabetes Federation, 2015, pp. 50-65). 
In 2013, Malaysia was ranked between the top ten countries in the world with 
impaired glucose tolerance (IGT) prevalence (>15%) among the population aged 20 – 79 
years as shown in Table 1.1. Impaired fasting glucose (IFG) along with, impaired glucose 
tolerance (IGT), is recognized as being a step former diabetes mellitus when blood glucose 
levels are higher than normal level. Thus, people with IGT are at elevated threat of getting 
type 2 diabetes. In more than one-third of individuals with IGT, blood glucose levels will 
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return to normal over a period of several years (International Diabetes Federation, 2013, 
p. 41; Shaw et al., 1999, pp. 399-402). 
Table 1.1. Highest Ten Countries/Territories for Prevalence (%) of Impaired 
Glucose Tolerance (20-79 years), 2013 and 2035 (Guariguata, et al., 2014, pp. 137-
49) 
Country/ Territory 2013 (%) Country/ Territory 2035 (%) 
Kuwait 17.9 Poland 19.3 
Qatar  17.1 Kuwait  18.1 
United Arab Emirates  16.6 Qatar  17.4 
Poland 16.5 United Arab Emirates  17.0 
Bahrain  16.3 Bahrain  16.7 
Malaysia  15.2 Malaysia  15.3  
Hong Kong SAR 13.3 Hong Kong SAR 13.2 
Nicaragua 12.9 Anguilla 13.0 
Japan  12.6 Guadeloupe  13.0 
Singapore 12.4 Macau SAR 12.9 
 
While the burden of diabetes continues to increase in Malaysia, the overall 
prevalence of diabetes in Malaysia was around twenty-three percent, where eleven percent 
was known diabetes, and twelve percent was new diabetes. Diabetes mellitus (DM) is a 
central public health issue in Malaysia and has been shown to be closely related to 
enhanced premature and preventable mortality, as well as macro and microvascular 
complications such as amputation heart disease, blindness, end-stage renal failure, and 
stroke (National Diabetes Registry Report, 2013, para. 1). 
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1.2.2 HbA1c 
HbA1c: A blood examination can quantify the amount of glycosylated hemoglobin 
in the blood. The assessment of HbA1c gives an indication about the mean of the level of 
an individual's glycemia for the last three months before the investigation. HbA1c can 
benefit in the evaluation to what extent an individual's glycemia is being within the target 
over time or not. Glucose molecules in the blood typically become cemented to 
hemoglobin molecules - this means the hemoglobin has developed into glycosylated (also 
reported as hemoglobin A1c or HbA1c). As an individual's blood sugar becomes higher 
than optimal blood glucose, more of the person's hemoglobin will become glycosylated. 
The glucose rests fixed to the hemoglobin for the lifecycle of the red blood corpuscles, or 
around sixty to ninety days (Guide to HbA1c, 2015, para. 1). 
Monitoring of glycosylated hemoglobin levels depends on the clinical needs of 
diabetic patient and his history of HbA1c control. The best practice in hemoglobin A1c 
monitoring is once per three months if trying to get better management or once per six to 
nine months if good control achieved and maintained (Guide to HbA1c, 2015, para. 1). 
1.2.3 Uncontrolled hyperglycemia 
Hyperglycemia is the circulation of an increased quantity of glucose higher than 
11.1 mmol/l (200 mg/dl) in the plasma of blood. The symptoms of diabetes may not start 
to become observable until even higher values such as 15-20 mmol/l (270-360 mg/dl). 
However, chronic levels exceeding 7mmol/L (125 mg/dl) can produce organ damage 
(American Diabetes Association, 2014, pp. S81-S90). 
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Uncontrolled diabetes mellitus or uncontrolled glycemia (UCG) is a diagnosis, 
which indicates that the person’s blood glucose level is not kept within normal levels by 
his or her current therapy regimen; it will be determined by measuring HbA1c. For non-
diabetics, the regular reading is (3.5 – 5.5%). For diabetic people, an HbA1c level of 6.5% 
is considered a good control, although some individuals may desire their numbers to be 
nearer to that of non-diabetics. American Diabetes Association (ADA) suggested that 
HbA1c more than seven percent is seen as UCG. The target of HbA1c, in general, is less 
than seven percent, designated according to the clinical practice and the predictable 
decrease in the diabetic complications through the treatment (American Diabetes 
Association, 2018, pp. S55-S64). 
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1.3 Cognition impairment  
Cognition is the conceptual achievement or procedure of receiving information 
and thoughtful to take action, throughout, understanding, feeling, and believed. It 
encompasses processes such as attention, learning, memory, and working memory, 
problem-solving and decision-making, computation, comprehension, evaluation, 
judgment, reasoning, and production of language (Oxford Dictionary, 2016, para. 1). 
Cognitive impairment is when a person has a problem with focusing, education new 
things, memorizing, building judgments or taking a decision that may affect their daily 
life. Cognitive deficit arrays from minor to severe. With mild cognitive impairment 
(MCI), persons may start to detect alterations in cognition functions, without disturbing 
their daily doings. Critical levels of cognitive decline can result in down the capability to 
comprehend the sense or meaning of something and capacity to dialog or using a pen, 
leading to the incapacity to depend on himself (Centers for Disease Control and 
Prevention, 2011, para. 1). 
Cognitive impairment is well-defined as a comprehensive term to interpret any 
characteristic that operates as an obstacle to the cognition procedure (Stanley, Ward & 
Enns, 1999, p. 9). The term may refer to deficits in learning disorders, or it may illustrate 
drug-induced cognitive/memory disability, such as that seen with benzodiazepines and 
alcohol (Kalachnik, Hanzel, Sevenich & Harder, 2002, pp. 376-410). It typically mentions 
as conflicting to the changed level of awareness, which may be severe and recoverable. 
Brain wounds may cause cognitive impairment, mental diseases or neurological 
conditions (Hockenbury & Sandy, 2004, para. 1). MCI has been proposed as a term for a 
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confined area among healthy aging and dementia, especially Alzheimer's disease (AD) 
(Hänninen, Hallikainen, Tuomainen, Vanhanen, & Soininen, 2002, pp. 148-54). 
1.3.1 Epidemiology of mild cognitive impairment (MCI) 
Prevalence evaluates of mild assorted from sixteen percent to twenty percent for 
the most of the analyzed research. A few studies had a very high estimation that could be 
due to issues with non-participation or elements particular to the survey method (Sachdev 
et al., 2012, pp. 854-65). Estimates from studies conducted in urban sites, multiethnic 
cohorts, and in clinic-based studies were also at the higher end of the spectrum (Roberts 
& Knopman, 2013, para. 1). 
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1.4 Complications of Diabetes 
Diabetes mellitus is a category of chronic disorders characterized by high blood 
glucose (hyperglycemia). The advanced medical therapy uses different ways of lifestyle 
modification and pharmaceutical interventions aimed at controlling and preventing 
hyperglycemia. In addition to confirming enough delivery of sugar to the body tissues, 
treatment of diabetes attempts to decrease the likelihood that hyperglycemia harms the 
tissues of the body. The significance of body protection from uncontrolled glycemia 
cannot be inflated; al the consequences of hyperglycemia on the vascular-tree of the body 
are the main basis of illness and death equally in all type of diabetes. The harmful effects 
of hyperglycemia are classified into microvascular complications (diabetic nephropathy, 
neuropathy, and retinopathy) and macrovascular disorders (coronary artery disease, 
peripheral arterial disease, and stroke). It is crucial for clinicians to comprehend the 
relationship between diabetes and vascular disease because the diabetes prevalence 
continues to increase in the world, and the clinical equipment for primary and secondary 
prevention of these complications are also expanding (Fowler, 2008, pp. 77-82). 
Benign prostatic hyperplasia (BPH) is a non-cancerous increase in the prostate 
size. Symptoms may involve frequent urination, trouble starting to urinate, weak stream, 
inability to urinate, or loss of bladder control. Complications can comprise bladder stones, 
urinary tract infections, and chronic renal problems (Kim, Larson & Andriole, 2016, pp. 
137-51). Using a histologic definition, the prevalence of BPH is higher than fifty percent 
by age sixty and almost ninety percent by age eighty-five (McConnell, Barry, & 
Bruskewitz, 1994, para. 1). A total of thirty-one prevalence rate estimations from twenty-
five countries were identified. The combined prevalence estimates showed that the 
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lifetime prevalence of BPH was about twenty-six percent (95% CI: 22.8–29.6%) (Lee, 
Chan, & Lai, 2017, pp. 1-10). 
Cataract is well defined as opaqueness of the lens clarity in the eye that decreases 
the extent of received lightness and leads to worsening of eyesight (Gupta, Rajagopala, & 
Ravishankar, 2014, pp. 103-10). The predominance of cataract without operation in 
persons with age of sixty or older was fifty-three percent in south India and fifty-eight 
percent in north India.  
The predominance of cataract in Koreans more than forty years of age was forty 
percent (Yoon, Mun, Kim, & Kim, 2011, pp. 421-33). In a National Eye Investigation, 
cataract was the main reason for thirty-nine percent of the two-sided loss of vision in 
Malaysia, whereas cataract responsible for sixty percent of the loss of sight and severe 
optical deficiency in Hanian region, China (Zainal, Ismail, Ropilah, & Elias, 2002, pp. 
951-56; Li, Liu, Liang, & Zhang, 2013, pp. 2176-83). In Indonesia, the predominance 
degree of any cataract for persons with age from twenty-one until twenty-nine was about 
one percent, snowballing to eighty-eight percent for persons with age more than sixty 
years old (Husain, Tong, Fong, Cheng, & How, 2005, pp. 1255-62; Thevi & Reddy, 2016, 
pp. 1-13). 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that 
makes a person feels increasingly difficult to breathe, breathlessness, excessive phlegm 
production, as well as a chronic cough. The condition mostly occurs in persons aged more 
than forty years and is mainly caused by smoking and smog in the atmosphere. (World 
Health Organization, 2015, para. 1). The prevalence of moderate to severe COPD in 
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Malaysia is nearly five percent which interprets to more than four-hundred and forty 
thousand patients (Ismail, 2009, pp. 250-56). 
Diabetic retinopathy (DR) is a microvascular complication that results from 
prolonged UCG (Ramachandran, Snehalatha, & Viswanathan, 2002, pp. 1471-76). DR is 
characterized by varying degrees of microaneurysms, hemorrhages, hard exudates, cotton 
wool spots, venous changes, new vessel formation, and macular thickening. It can involve 
the peripheral retina, the macula, or both. Diabetic eye illness is the main reason for 
blindness in the Malaysian persons at the age of work. The prevalence of DR in Malaysia 
has been reported to range from forty-four to forty-nine percent (Tajunisah, Nabilah & 
Reddy, 2006, pp. 451-56). The United Kingdom Prospective Diabetes Study (UKPDS), 
in which thirty-nine percent of men and thirty-five percent of women had DR at the time 
of diagnosis (Mohd Ali, Draman, Mohamed, Yaakub & Embong, 2016, pp. 353-58). 
Erectile dysfunction (ED) is a situation in which a male is unable to achieve or 
maintain a penile erection firm enough for satisfactory sexual intercourse (Nunes, Labazi 
& Webb, 2012, pp. 163-70). ED occurs in about 12% of men younger than 60, about 22% 
of men age 60 to 69 and 30% of men age 70 or older (Heidelbaugh, 2010, pp. 305-12). 
Data from the Massachusetts Male Aging Study (MMAS) stated that 52% of men aged 
40-70 years, reported erectile dysfunction in Massachusetts, United States (Muneer, Kalsi, 
Nazareth, & Arya, 2014, pp. 1-9).  
Peripheral neuropathy (PN) is a neuron illness. It can result in discomfort, 
faintness, numbness, sting, and tingling. The signs typically start in the lengthiest body 
nerves and so primary distress the legs and fingers. PN is sometimes called the “stocking-
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glove” pattern. The symptoms usually extend slowly and evenly up the arms and legs. 
Other body parts might also be influenced. Most individuals who develop PN are over the 
age of fifty-five years. But persons can be affected at any age (American Academy of 
Neurology, 2012, para 1). Peripheral neuropathy is a significant cause of disability 
worldwide. Diabetes is the primary common cause of neuropathy, accounting for fifty 
percent of cases (International Diabetes federation, 2011, para. 1). Over half of diabetic 
people develop neuropathy, and twenty percent of type 2 diabetic patients have diabetic 
peripheral neuropathy (DPN) at diabetes presentation. DPN is a significant cause of 
reduced quality of life due to pain, sensory loss, gait instability, fall‐related injury, and 
foot ulceration and amputation (Stino & Smith, 2017, pp. 646-55). 
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1.5 Statement of the problem 
Current evidence indicates that statins enhance the incidence of diabetes; however, 
the relationship between glycemic control in patients with established diabetes and statins 
has not been well-characterized (Erqou, Lee, & Adler, 2014, pp. 2444-52). There are 
drawbacks in the prior research that have investigated the diabetogenic effect of statins 
therapy and its impact on HbA1c control in Malaysia. Investigating the impacts of statin 
therapy on glycemia controlling in diabetic persons is worthy since statins are 
consequently prescribed to most of the diabetic patients.  
Moreover, the Mini-Addenbrooke's Cognitive Examination (M-ACE) is a novel 
assessment tool for cognition deficit developed in 2015 (Hsieh et al., 2015, pp. 1-11). 
Until the date of starting the present study, M-ACE was not translated or adapted to Malay. 
Further, M-ACE was not applied among the Malaysian population to detect cognitive 
decline in diabetic patients under statin therapy. 
The association between diabetic complications and statins therapy has not been 
reported in Malaysia, thus deserves further study. Moreover, the need for evaluation of 
healthcare awareness about statins use and its adverse effects. There is a requirement of 
investigation the impact of postgraduate qualification on the healthcare awareness of 
statins usage in the management of diabetic dyslipidemia.  
Medication safety is always very important issue especially with the statins, for 
many reasons. First, and perhaps the most important factor, statins are frequently 
prescribed. Statins are the single major prescribed category of drugs, in dollar value, in 
the United States today. Second, they are prescribed for a prolonged duration of patient’ 
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life. Over the many years that a typical patient takes a statin, there are many chances for 
adverse events, including unexpected changes in the patient's health status. A third and 
critical factor is that statins are most commonly used in middle-aged or elderly patients, 
who tend to be prescribed many other medicines for other diseases. The advanced age 
heightens safety concerns, both because the polypharmacy typical of these age groups 
significantly increases the overall risk of drug-drug interactions. Also because many of 
the diseases prevalent in older patients contribute to drug safety concerns, and finally, 
because of advanced age itself, probably increases the risk of drug side effects and toxicity 
(Brinton, 2004, para. 1). 
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1.6 The significance of the study 
The majority of studies about the effect of statin on HbA1c control and diabetes 
complications were conducted in developed countries, but the studies of diabetogenic 
impacts of statin in Malaysia are still limited. Research results on the epidemiology and 
clinical characteristics of diabetogenic effects of statins in Malaysia can be used for better 
control of HbA1c, FBG, and avoidance the complications of diabetes. A unique feature of 
this study population can also be used for participation in global trails and a better 
understanding of the diabetogenic effect of statins. 
Limited data are available about the effect of statins on HbA1c control in Malaysia, 
and there is probably no information on the baseline characteristics, the comparison 
between different doses, various members of statins, cognition impairment and diabetic 
complication among statins users. This information can assist in distinguishing between 
the overall effects of different statins members. 
Also, there are no updated data on the prevalence of statins utilization in Malaysia. 
These results can help to improve evidence-based treatment by achieving the optimal 
benefit from statins while minimizing their side effects and diabetes complications. 
Moreover, controversial data are available on the consequences of statins utilization on 
the diabetic complications; information from the study can assist in clearing the situation 
and improve the quality of life for the patients.  Obtaining these data can increase the 
awareness about statins effects on HbA1c and diabetic complications, and help in the 
quick detection and prevention of this problem.  
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If diabetic patients decrease their HbA1c level by one percent, there is about 
nineteen percent reduction in cataract extractions, sixteen percent decrease in heart failure 
and forty-three percent reduction in amputation or death due to peripheral vascular disease 
(Guide to HbA1c, 2015, para. 1). Therefore, the optimization of statins therapy will reflect 
on more achievement of HbA1c control that result in the reduction of diabetic 
complication and increase the survival rate among the diabetic patients. 
Identifying the effect of statins use on the HbA1c controlling in Malaysian, 
Chinese and Indian ethnicity. The outcomes of the study may play as a base for thinking 
about the pharmacogenetic effect of statins among various ethnicity of diabetic patients. 
The findings may be a key for thinking about the alternative of statins drugs to 
decrease the incidence rate of new onset diabetes mellitus and optimize the glycemic 
control, which reduces the suffering of patients from the complications of diabetes 
mellitus. The decline of statins using, the reduction of diabetes incidence and achieving 
blood glucose target will result in a decrease of the direct and indirect cost of diabetes 
illness. Results will help in patient care improvement, increasing patient quality of life 
and survival rate. 
Mild cognitive impairment (MCI) is a stage that is potentially amenable to 
interferences that may avoid more deterioration toward dementia; the stage of cognitive 
dysfunction that has a more massive effect on the everyday behavior. The study may 
afford a more understanding of MCI and share to early detection of subjects with MCI. 
Patients with MCI may benefit from interventions that will decrease their risk of 
progression to dementia and may be eligible for treatment with disease-modifying drugs 
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that reverse previous damage or prevent further decline when such therapy become 
available (Roberts & Knopman, 2013, pp. 753-72).  
The Malay version of the M-ACE is a brief, reliable, and very useful screening 
tool for the assessment of cognitive deficiency and has shown to discriminate between 
MCI and dementia. This study is among the earliest to apply the M-ACE to a Malay-
speaking population. The Malay version of the M-ACE can use as a tool for cognitive 
examination in the outpatients setting, highly crowded clinics and research. 
The study explored the prevalence of cognition impairment, benign prostatic 
hyperplasia (BPH), cataract, COPD, diabetic retinopathy, erectile dysfunction (ED) and 
peripheral neuropathy incidence among type 2 diabetic outpatients in the Malaysian 
population. Moreover, the study revealed the effect of statins on cognitive impairment, 
BPH, cataract, COPD, DR, ED, and PN which help in the optimization of statins therapy 
in diabetic dyslipidemia management (DDM). 
The evaluation of awareness and knowledge of the healthcare team about statins 
use and its adverse effects, which can be a base for future training and continuous 
professional development.  
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1.7 Research questions 
 What is the prevalence of uncontrolled glycemia and statins prescribing amongst type 
2 diabetic persons? 
 Does statin utilization increase or decrease HbA1c and fasting blood glucose among 
diabetic people? 
 Do the various doses of statins have the same effect on HbA1c? 
 Do the various members of statins have the same impact on HbA1c? 
 Does the HbA1c control have an impact on morbidity and estimated 10-year survival 
(ES-10Y)? 
 What is the effect of statins on cognition among diabetic individuals? 
 What is the prevalence of non-cardiovascular clinical outcomes and the influence of 
statins on non-cardiovascular clinical outcomes among diabetic patients? 
 What is the level of healthcare professionals’ awareness toward the use of statins in 
the management of diabetic dyslipidemia? 
 What is the effect of postgraduate qualification, gender and the type of job (pharmacist 
vs. physician) on the awareness of statin use in the management of diabetic 
dyslipidemia? 
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1.8 Objectives 
1.8.1 Primary objectives 
1.8.1.1 To assess the effect of statins usage on HbA1c control and fasting blood glucose. 
1.8.1.2 To evaluate the healthcare providers’ awareness and attitude about statins use. 
1.8.2 Secondary objectives  
1.8.2.1 To match the influences of different dosages of statins (High, moderate and low 
intensity) on HbA1c control. 
1.8.2.2 To explore the effect of the various members of statins (for equivalent doses) on 
HbA1c control.  
1.8.2.3 To evaluate the impact of glycated hemoglobin control on morbidity and 
estimated 10-year survival (ES-10Y). 
1.8.2.4 To assess the effect of statin use on cognitive function.  
1.8.2.5 To determine the effect of statins on diabetic complications incidence among 
type 2 diabetic outpatients. 
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1.9 Justification of the study 
The present study was conducted to detect the gap in the adherence of healthcare 
providers by clinical treatment guidelines in the management of diabetic dyslipidemia. 
The findings from the survey will enable the policy makers to identify the zones where 
improvement should be highlighted regarding the application of treatment guidelines, 
recommendations, and statins therapy optimization. If these gaps are addressed, hopefully, 
this would lead to reduced incidence of diabetic related complications and decrease the 
cost of illness. The study also sought to afford baseline data on the prevalence of diabetic 
complications associated with statins therapy in an understudied area. 
These data can be considered as a reference point against which the effectiveness 
of any future intervention to improve diabetic and cognitive impairment management can 
be measured. Lastly, gaps in healthcare awareness, attitude and practice were identified, 
and these will form the basis of continuing professional education and training to improve 
the pharmacological interventions and practice of the healthcare providers. The net result 
of the findings will reflect on improving the rational use of medications, advancing patient 
care, advanced practice, and sustainable improvement of patients’ quality of life. 
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AIDS: Acquired immune deficiency syndrome, BPH: Benign prostatic hyperplasia, COPD: Chronic obstructive 
pulmonary disease, DM: Diabetes mellitus, HbA1c: Glycated hemoglobin, HIV: Human immunodeficiency virus, PN: 
peripheral neuropathy. 
Figure 1.1. The framework of the thesis
Diabetic cases were 
scanned for HbA1c test
Type 2 diabetic patients 
have HbA1c test 
Patients with type 2 
diabetes mellitus
(Prospective study)
Cohort of 200 
patients are 
using statin 
Patients with 
HbA1c > 7%
Patients with 
HbA1c ≤ 7%
Cohort of 200 
patients do not 
use statin 
Patients with  
HbA1c > 7%
Patients with 
HbA1c ≤ 7%
Patients ≥ 40 
years (MACE 
among statin 
users)
Patients with 
cognitive 
impairment
Patients without 
cognitive 
impairment
Patients≥ 40 
years (MACE 
among statin 
non-users)
Patients with 
cognitive 
impairment
Patients without 
cognitive 
impairment
Exclusion criteria:
Patients with pregnancy, cancer, 
HIV, AIDS, hypothyroidism, 
hyperthyroidism and liver 
cirrhosis and patient < 18 years 
Patients did not 
have HbA1c test 
To explore the effect of statins 
usage on BPH, cataract, COPD, 
diabetic retinopathy, erectile 
dysfunction, and PN 
(Retrospective study) 
 
H
ea
lt
h
ca
re
 a
w
ar
en
es
s 
ab
o
u
t 
u
se
 o
f 
st
at
in
s 
am
o
n
g
 p
at
ie
n
ts
 w
it
h
 t
y
p
e 
2
 D
M
 (
K
A
P
 s
tu
d
y
) 
Study 
Phases 
Phase 1 Phase 2 
24 
 
CHAPTER 2 : LITERATURE REVIEW 
Statin treatment is the keystone of primary and secondary prevention of 
cardiovascular disease (The Emerging Risk Factors Collaboration, 2010, pp. 2215-22). 
Diabetes is a significant hazard factor for cardiovascular diseases (CVD) and is recognized 
as a cardiovascular (CV) risk equivalent. Therapy guidelines indicate that most of the 
diabetic patients would benefit from statin therapy (Cholesterol Treatment Trialists’ 
(CTT) Collaborators et al., 2008, pp. 117-25; National Cholesterol Education Program, 
2002, pp. 3143-421; Rocco, 2012, pp. 883-93). Recent clinical recommendations from the 
American College of Cardiology and the American Heart Association stated that all 
diabetic patients who are forty to seventy-five years of age should be placed on moderate 
or high-intensity statin treatment to avoid or delay CVD (Stone et al., 2014, pp. S1-45).  
Although their crucial role in the avoidance and postponement of CVD, there is 
proof proposing that statins deteriorate blood glucose level and raise the hazard of 
emerging type 2 diabetes by around ten to twelve percent (Sattar et al., 2010, pp. 735-42; 
Maki et al., 2014, pp. S17-29). The consequence of statins therapy on the occurrence of 
diabetes seems to vary by dosage and kind; high dosages result in a higher threat than 
lesser dosages (Preiss et al., 2011, pp. 2556-64). Moreover, rosuvastatin and atorvastatin 
are concomitant with a higher hazard than pravastatin (Carter et al., 2013, para. 1). On the 
other hand, the consequence of statins on HbA1c and blood glucose in persons with pre-
existing diabetes is indistinct.  
 
